RxDoctor Payments Data

Matthew Perkins, MD

Internal Medicine · Smyrna, TNNPI 1346238656

Payments from drug & device makers

$4,852in general payments, 2019–2025

Across 299 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$946
  • Pfizer$358
  • Lilly USA, LLC$313
  • AstraZeneca$184
  • Merck$158
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,852 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$82,569
Medicare patients
245
Services billed
1,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$90,367
MounjaroTirzepatide28$35,971
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$34,644
JanumetSitagliptin Phos/Metformin Hcl30$33,282
OzempicSemaglutide26$31,537
Janumet XrSitagliptin Phos/Metformin Hcl14$21,716
Soliqua 100-33Insulin Glargine/Lixisenatide12$21,337
JanuviaSitagliptin Phosphate24$20,627
JardianceEmpagliflozin11$16,857
XareltoRivaroxaban14$11,105
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp30$9,761
LinzessLinaclotide12$9,049
Trijardy XrEmpaglifloz/Linaglip/Metformin13$8,429
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,299
Breo ElliptaFluticasone/Vilanterol19$8,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$358$90,367109 claims
MerckJanumet, Janumet Xr, Januvia$158$75,62568 claims
Boehringer IngelheimJardiance, Trijardy Xr, Jentadueto, Spiriva Respimat$92$37,27247 claims
Lilly USA, LLCMounjaro$313$35,97128 claims
Novo NordiskOzempic$946$31,53726 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$83$21,33712 claims
Johnson & JohnsonXarelto$74$11,10514 claims
AbbVieLinzess$1,001$9,04912 claims
AstraZenecaBreztri Aerosphere$184$8,29912 claims
GSKBreo Ellipta$144$8,04019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Smyrna

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →